Sarah A. Friedman , Paul Snyder , Denis Patterson , Sarah Y.T. Hartzell , Michelle S. Keller
{"title":"在长期使用阿片类药物的医疗补助患者中减少阿片类药物的处方","authors":"Sarah A. Friedman , Paul Snyder , Denis Patterson , Sarah Y.T. Hartzell , Michelle S. Keller","doi":"10.1016/j.josat.2025.209695","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Guidelines encourage deprescribing opioids for long-term opioid patients, especially those using opioids and benzodiazepines, z-drugs, or muscle relaxants (“other respiratory depressants”).</div></div><div><h3>Objective</h3><div>Were long-term opioid patients who were prescribed other respiratory depressants more likely to have deprescribing opioid trajectories?</div></div><div><h3>Design</h3><div>Cross-sectional retrospective study using pharmacy and professional claims from 2015 to 2019. Adjusted logistic regression models were stratified on low (<50 morphine milligram equivalents; MME) and high (>50 MME) starting opioid doses. We reported predicted probabilities with 95 % confidence intervals.</div></div><div><h3>Subjects</h3><div>Nevada and Colorado Medicaid beneficiaries 18–64 years old without cancer diagnoses with long-term (120 days' supply/6 months) opioid use (117,400 person-windows).</div></div><div><h3>Measures</h3><div>We used group-based trajectory modeling in Stata to identify characteristic 12-month dosing trajectories. Using the resulting trajectories, we assigned the outcome = 1 if the observation had a deprescribing trajectory (versus a constant trajectory). Binary exposure variables indicated that the patient had an opioid prescription overlapping with 1, 2, or 3 types of other respiratory depressants.</div></div><div><h3>Results</h3><div>Among patients with a low starting opioid dose, the predicted probabilities of a deprescribing trajectory were lower when the patient had overlapping other respiratory depressants compared to when they did not (0 respiratory depressants: 0.33, [0.32, 0.33]; vs. 1 respiratory depressant: 0.22, [0.20, 0.23]; 2 respiratory depressants: 0.18 [0.16, 0.20]; 3 respiratory depressants:0.20 [0.13, 0.27]). Among patients with a high starting opioid dose, we observed similar results.</div></div><div><h3>Conclusions and relevance</h3><div>Targeted provider-level interventions to support deprescribing for long-term opioid patients using opioids and other respiratory depressants may provide particularly high-value care.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"174 ","pages":"Article 209695"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"De-prescribing opioids among Medicaid patients with long-term opioid use\",\"authors\":\"Sarah A. Friedman , Paul Snyder , Denis Patterson , Sarah Y.T. Hartzell , Michelle S. Keller\",\"doi\":\"10.1016/j.josat.2025.209695\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Guidelines encourage deprescribing opioids for long-term opioid patients, especially those using opioids and benzodiazepines, z-drugs, or muscle relaxants (“other respiratory depressants”).</div></div><div><h3>Objective</h3><div>Were long-term opioid patients who were prescribed other respiratory depressants more likely to have deprescribing opioid trajectories?</div></div><div><h3>Design</h3><div>Cross-sectional retrospective study using pharmacy and professional claims from 2015 to 2019. Adjusted logistic regression models were stratified on low (<50 morphine milligram equivalents; MME) and high (>50 MME) starting opioid doses. We reported predicted probabilities with 95 % confidence intervals.</div></div><div><h3>Subjects</h3><div>Nevada and Colorado Medicaid beneficiaries 18–64 years old without cancer diagnoses with long-term (120 days' supply/6 months) opioid use (117,400 person-windows).</div></div><div><h3>Measures</h3><div>We used group-based trajectory modeling in Stata to identify characteristic 12-month dosing trajectories. Using the resulting trajectories, we assigned the outcome = 1 if the observation had a deprescribing trajectory (versus a constant trajectory). Binary exposure variables indicated that the patient had an opioid prescription overlapping with 1, 2, or 3 types of other respiratory depressants.</div></div><div><h3>Results</h3><div>Among patients with a low starting opioid dose, the predicted probabilities of a deprescribing trajectory were lower when the patient had overlapping other respiratory depressants compared to when they did not (0 respiratory depressants: 0.33, [0.32, 0.33]; vs. 1 respiratory depressant: 0.22, [0.20, 0.23]; 2 respiratory depressants: 0.18 [0.16, 0.20]; 3 respiratory depressants:0.20 [0.13, 0.27]). Among patients with a high starting opioid dose, we observed similar results.</div></div><div><h3>Conclusions and relevance</h3><div>Targeted provider-level interventions to support deprescribing for long-term opioid patients using opioids and other respiratory depressants may provide particularly high-value care.</div></div>\",\"PeriodicalId\":73960,\"journal\":{\"name\":\"Journal of substance use and addiction treatment\",\"volume\":\"174 \",\"pages\":\"Article 209695\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of substance use and addiction treatment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949875925000748\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"0\",\"JCRName\":\"PSYCHOLOGY, CLINICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of substance use and addiction treatment","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949875925000748","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"0","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
De-prescribing opioids among Medicaid patients with long-term opioid use
Background
Guidelines encourage deprescribing opioids for long-term opioid patients, especially those using opioids and benzodiazepines, z-drugs, or muscle relaxants (“other respiratory depressants”).
Objective
Were long-term opioid patients who were prescribed other respiratory depressants more likely to have deprescribing opioid trajectories?
Design
Cross-sectional retrospective study using pharmacy and professional claims from 2015 to 2019. Adjusted logistic regression models were stratified on low (<50 morphine milligram equivalents; MME) and high (>50 MME) starting opioid doses. We reported predicted probabilities with 95 % confidence intervals.
Subjects
Nevada and Colorado Medicaid beneficiaries 18–64 years old without cancer diagnoses with long-term (120 days' supply/6 months) opioid use (117,400 person-windows).
Measures
We used group-based trajectory modeling in Stata to identify characteristic 12-month dosing trajectories. Using the resulting trajectories, we assigned the outcome = 1 if the observation had a deprescribing trajectory (versus a constant trajectory). Binary exposure variables indicated that the patient had an opioid prescription overlapping with 1, 2, or 3 types of other respiratory depressants.
Results
Among patients with a low starting opioid dose, the predicted probabilities of a deprescribing trajectory were lower when the patient had overlapping other respiratory depressants compared to when they did not (0 respiratory depressants: 0.33, [0.32, 0.33]; vs. 1 respiratory depressant: 0.22, [0.20, 0.23]; 2 respiratory depressants: 0.18 [0.16, 0.20]; 3 respiratory depressants:0.20 [0.13, 0.27]). Among patients with a high starting opioid dose, we observed similar results.
Conclusions and relevance
Targeted provider-level interventions to support deprescribing for long-term opioid patients using opioids and other respiratory depressants may provide particularly high-value care.